StockData
Ovid Therapeutics Inc. logo

Ovid Therapeutics Inc. (OVID) stock

OVIDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 10/30
$2.22−0.18 (-7.50%)

Close on Nov 17, 2026Market cap $433.56MP/E –Yield –

Ovid Therapeutics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Ovid Therapeutics's price to sales ratio was 324.5× on Nov 11, 2026, against 19.2× a year earlier. Over the last 5 years it ranged from 0.9× to 457.0×, with a median of 64.1×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 2026324.5×+306.9
2025Dec 31, 202517.5×−87.4
2024Dec 31, 2024104.9×−63.0
2023Apr 28, 2023167.9×+77.9
2022Dec 30, 202290.0×+89.0
2021Dec 31, 20211.0×–

More Ovid Therapeutics figures

See a number that looks wrong?